Schizophrenia: Treating a Chronic Disease with a Focus on Early Intervention, Adherence, and Recovery
neuroscienceCME Live and On Demand
Premiere Date: Wednesday, August 12, 2009Click here to access additional resources mentioned in the live broadcast.
This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Psychologists (APA)
- Social Workers (NASW)
- Certified Case Managers (CCMC)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, August 12, 2010
Note: Credit Is No Longer Available
 | John W. Newcomer, MD (Moderator) Senior Associate Dean for Clinical Research Leonard M. Miller Professor of Psychiatry and Behavioral Sciences Leonard M. Miller School of Medicine University of Miami Miami, FL |
 | Diana O. Perkins, MD, MPH Professor, Department of Psychiatry Director, (OASIS) Outreach and Support Intervention Services University of North Carolina School of Medicine Chapel Hill, NC Director, Early Psychosis Interventions in North Carolina (EPI-NC) |
 | Alexander S. Young, MD, MSHS Professor, UCLA Department of Psychiatry Director, Health Services VA Desert Pacific Mental Illness Research, Education and Clinical Center Los Angeles, CA |
Schizophrenia is notable for its substantial impact on everyday functioning, being one of the top five causes
of disability in individuals under the age of 25. In most cases, individuals who develop schizophrenia manifest
behavioral changes prior to the formal diagnosis of the condition. These changes, referred to as the "prodrome,"
are variable across individuals who may eventually develop schizophrenia.(1,2) Proactive risk assessment in other
chronic diseases such as cardiovascular disease, diabetes mellitus, and cancer has brought about advances in
early detection and intervention leading to substantial reductions in morbidity, mortality, and improved quality
of life. It is imperative that this type of proactive intervention becomes part of timely diagnosis and better
outcomes for patients with schizophrenia.
Clinicians face challenges designing treatment plans for patients with schizophrenia that will maximize
adherence and reduce side effects. Relapse rates tend to be quite predictable, can be affected by adherence,
and have multiple adverse consequences. Minimizing relapse requires a coordinated effort between the
patient, provider, family, and multidisciplinary treatment team. In this interactive neuroscienceCME activity,
faculty will focus on the impact of treatment selection, phase of illness, medication adherence, and side effect
burden on the journey toward remission and recovery in schizophrenia.
- Cannon TD, et al. Arch Gen Psychiatry 2008;65:28-37.
- Correll CU, et al. J Child Adolesc Psychopharmacol 2005;15:418-433.
To identify and utilize evidence-based management strategies to improve outcomes for patients with schizophrenia.
At the end of this CE activity, participants should be able to:
- Utilize available tools and evidence base to improve early recognition of schizophrenia.
- Identify the key considerations that may impact adherence and outcomes when creating a treatment plan.
- Create a treatment plan that includes patients, families, and the treatment team and utilizes the Competency Assessment Instrument to focus on recovery.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify available tools and evidence base to improve early recognition of schizophrenia.
- Identify the key considerations that may impact adherence and outcomes when creating a treatment plan.
- Identify critical elements of a treatment plan that includes patients, families, and the treatment team and utilizes the Competency Assessment Instrument (CAI) to focus on recovery.
This activity is supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
This CME/CE-certified activity is funded by CME Outfitters, LLC, and supported by an educational grant from Pfizer Inc.
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals with an interest in mental health.
CME Credit (Physicians):
The University of Texas
Southwestern Medical Center is accredited by the Accreditation
Council for Continuing Medical Education to provide
continuing medical education for physicians.
The University of Texas
Southwestern Medical Center designates this educational
activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
Physicians should only claim credit commensurate with the
extent of their participation in the activity.
CNE Credit (Nurses):
This continuing nursing education
activity was approved by the New York State Nurses
Association, an accredited approver by the American Nurses
Credentialing Center’s Commission on Accreditation.
It has been assigned approval code 7YDSRT-10. 1.0 contact
hours will be awarded upon successful completion.
CEP Credit (Psychologists):
CME Outfitters is approved by
the American Psychological Association to sponsor continuing
education for psychologists. CME Outfitters maintains
responsibility for this program and its content. (1.0 CE credits)
NASW Credit (Social Workers):
This program was approved
by the National Association of Social Workers (provider
#886407722) for 1 continuing education contact hour.
CCMC Credit (Certified Case Managers):
This program has
been approved for 1 hour by the Commission for Case Manager
Certification (CCMC).
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by
the Accreditation Council for Pharmacy Education as a
provider of continuing pharmacy education.
1.0 contact hours (0.1 CEUs)
Universal Program Number:
376-999-09-019-L01-P (live presentation)
376-999-09-019-H01-P (recorded programs)
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations can be
completed online at www.neuroscienceCME.com (click on the
Testing/Certification link under the Activities tab—requires free
account activation), and participants can print their certificate
or statement of credit immediately (70% pass rate required).
Otherwise, participants should fully complete and return both
the credit request form and activity evaluation located within the
course guide for this activity. A certificate or statement of credit
will be mailed within 4–6 weeks to all who successfully complete
these requirements. This website supports all browsers except
Internet Explorer for Mac. For complete technical requirements
and privacy policy, visit www.neuroscienceCME.com/technical.asp.
This continuing education activity is co-sponsored by The University of Texas Southwestern Medical Center and CME Outfitters, LLC.
Disclosure Declaration
It is the policy of The University of Texas Southwestern Medical Center and CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. All decisions to invite faculty were made by The University of Texas Southwestern Medical Center and CME Outfitters, LLC, independent of any commercial interest. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. The University of Texas Southwestern Medical Center and CME Outfitters, LLC, have evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Newcomer has disclosed that he receives grant support from The National Institute of Mental Health, The National Alliance for Research on Schizophrenia and Depression, Bristol-Myers Squibb Company, Janssen, L.P.; Pfizer Inc., and Wyeth Pharmaceuticals. He serves as a consultant to AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, litigation regarding medication effects, GlaxoSmithKline, H. Lundbeck A/S, Janssen, L.P., Organon Pharmaceuticals USA Inc., Otsuka America Pharmaceutical, Inc., Pfizer Inc., Solvay Pharmaceuticals, Inc., Tikvah Therapeutics, Inc., VANDA Pharmaceuticals, and Wyeth Pharmaceuticals. He serves on the data safety monitoring committee of Dainippon Sumitomo Pharma America, Inc., Organon Pharmaceuticals USA Inc., Schering-Plough Corporation, and Vivus, Inc. Dr. Newcomer also receives product development royalties for Metabolic Screening forms from Compact Clinicals/Jones and Bartlett Publishing.
Dr. Perkins has disclosed that she receives grant/research support from Janssen, L.P. She serves as a consultant to Dainippon Sumitomo Pharma. She is on the speakers bureau for Eli Lilly and Company.
Dr. Young has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
The University of Texas Southwestern Medical Center, CME Outfitters, LLC, the faculty, Lilly USA, LLC, and Pfizer Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
TV-061-081209-90
